- Recognition of tumor neoantigens by autologous T cells activates immune surveillance and has been reported to promote sensitivity to immune checkpoint inhibitors (ICI) in mismatch repair deficient (MMRd)/microsatellite instability high (MSI-H) tumors.
- Neoantigen-targeted reactivity has also been reported in microsatellite stable (MSS) tumors.
- Neoantigens are emerging targets for novel immunotherapy strategies, including tumor vaccines, in BC and PC.
- We aimed to comprehensively assess the spectrum of immunogenic neoantigens in BC and PC.
Publications
Identification and characterization of immunogenic neoantigens in biliary cancer (BC) and pancreatic cancer (PC)
– Caris Life Sciences